RYTM
Rhythm Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-23/100
Last price
90.77
▼ 1.68 (1.82%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
88.00
Prev close
92.45
Day high
94.47
Day low
90.07
Volume
992.87K
Market cap
$6.25B
P/E (TTM)
—
52W range
74.50 – 122.20
Day trading desk
Gap from prior close
-4.81%
Prior close 92.45
VWAP
91.14
-0.41% from price
Relative volume
2.60×
Unusually busy
Session range
9.34%
87.80 – 96.00
Position in range
36%
Mid range
ATR (14D)
3.53
3.88% of price
Prior day high
94.41
PDH
Prior day low
89.53
PDL
Bid / ask spread
—
Quote not published
Session volume
1.68M
Avg 646.39K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.16%
-7.1%
1M
-11.65%
-12.8%
3M
-20.68%
-25.2%
6M
+4.74%
-13.4%
YTD
-15.20%
-29.4%
1Y
-8.33%
-24.8%
3Y
+295.94%
+213.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RYTM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-15.21K
Net selling
Buy transactions
14
284.88K shares
Sell transactions
8
300.09K shares
Net transactions
+22
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
481.96K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 14, 26 | MEEKER DAVID P Chief Executive Officer |
CONVERSION | 50.00K | $302.50K | Direct |
| Sep 14, 26 | MEEKER DAVID P Chief Executive Officer |
SELL | 50.00K | $5.13M | Direct |
| Aug 31, 26 | SMITH HUNTER C Chief Financial Officer |
CONVERSION | 57.19K | $1.47M | Direct |
| Aug 31, 26 | SMITH HUNTER C Chief Financial Officer |
SELL | 62.77K | $6.62M | Direct |
| Aug 13, 26 | LEE JENNIFER KAYDEN Officer |
CONVERSION | 56.60K | $997.04K | Direct |
| Aug 13, 26 | SHULMAN JOSEPH J Chief Technology Officer |
CONVERSION | 2.02K | $13.76K | Direct |
| Aug 13, 26 | SHULMAN JOSEPH J Chief Technology Officer |
SELL | 5.08K | $608.21K | Direct |
| Aug 13, 26 | GARFIELD ALASTAIR PH.D. Officer |
SELL | 7.76K | $912.70K | Direct |
| Aug 13, 26 | LEE JENNIFER KAYDEN Officer |
SELL | 75.83K | $8.90M | Direct |
| Aug 12, 26 | MAZABRAUD YANN Officer |
CONVERSION | 46.63K | $317.05K | Direct |
| Aug 12, 26 | MAZABRAUD YANN Officer |
SELL | 57.00K | $6.62M | Direct |
| Jul 1, 26 | GARFIELD ALASTAIR PH.D. Officer |
— | 4.45K | — | Direct |
| Jun 23, 26 | GOOD JENNIFER L Director |
— | 4.71K | — | Direct |
| Jun 23, 26 | MCGIRR DAVID W J Director |
— | 4.71K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CRAMER PAMELA J. |
Officer | 29.38K | Conversion of Exercise of derivative security |
GOOD JENNIFER L |
Director | 11.71K | Conversion of Exercise of derivative security |
JEAN CHRISTOPHE R |
Director | 11.71K | Conversion of Exercise of derivative security |
MATHERS EDWARD T. |
Director | 12.77K | Conversion of Exercise of derivative security |
MAZABRAUD YANN |
Officer | 55.66K | Conversion of Exercise of derivative security |
MCGIRR DAVID W J |
Director | 11.71K | Conversion of Exercise of derivative security |
MEEKER DAVID P |
Chief Executive Officer | 239.26K | Conversion of Exercise of derivative security |
SHULMAN JOSEPH J |
Chief Technology Officer | 15.91K | Conversion of Exercise of derivative security |
SMITH HUNTER C |
Chief Financial Officer | 114.02K | Conversion of Exercise of derivative security |
TETRAULT LYNN A. |
Director | 11.71K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$6.25B
Enterprise value$6.14B
Revenue (TTM)$239.92M
Gross profit$213.53M
EBITDA$-199.55M
Net income$-210.22M
EPS (TTM)$-3.06
Free cash flow$-130.59M
Total cash$330.90M
Total debt$109.78M
Book value / share$1.50
Shares outstanding68.85M
Float56.04M
Short % of float15.06%
Dividend yield0.00%
Beta (5Y)2.01
Valuation & profitability ratios
Trailing P/E—
Forward P/E-148.17
PEG ratio—
Price / sales—
Price / book60.68
EV / revenue25.60
EV / EBITDA-30.78
Gross margin89.00%
Operating margin-68.14%
Profit margin-85.59%
Return on equity-117.05%
Return on assets-30.96%
Debt / equity50.52
Current ratio3.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $189.76M | $130.13M | $77.43M | $23.64M | +45.8% |
| Operating revenue | $189.76M | $130.13M | $77.43M | $23.64M | +45.8% |
| Cost of revenue | $19.49M | $13.37M | $9.30M | $2.13M | +45.8% |
| Gross profit | $170.26M | $116.76M | $68.13M | $21.50M | +45.8% |
| Research & development | $167.34M | $237.96M | $134.95M | $108.63M | -29.7% |
| Selling, general & admin | $194.94M | $144.30M | $117.53M | $92.03M | +35.1% |
| Total operating expense | $362.28M | $382.26M | $252.48M | $200.66M | -5.2% |
| Operating income | -$192.02M | -$265.50M | -$184.36M | -$179.16M | +27.7% |
| Net interest income | -$5.29M | -$5.89M | $53.00K | -$1.17M | +10.2% |
| Pre-tax income | -$196.04M | -$260.26M | -$184.11M | -$181.12M | +24.7% |
| Tax provision | $497.00K | $346.00K | $564.00K | $0 | +43.6% |
| Net income | -$196.54M | -$260.60M | -$184.68M | -$181.12M | +24.6% |
| Net income to common | -$201.92M | -$264.57M | -$184.68M | -$181.12M | +23.7% |
| Basic EPS | -3.11 | -4.34 | -3.20 | -3.47 | +28.3% |
| Diluted EPS | -3.11 | -4.34 | -3.20 | -3.47 | +28.3% |
| EBIT | -$175.46M | -$239.65M | -$170.22M | -$175.92M | +26.8% |
| EBITDA | -$174.12M | -$238.09M | -$168.46M | -$174.25M | +26.9% |
| Basic shares | 64.98M | 61.00M | 57.67M | 52.12M | +6.5% |
| Diluted shares | 64.98M | 61.00M | 57.67M | 52.12M | +6.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $54.30M | $89.14M | $60.08M | $127.68M | -39.1% |
| Cash & short-term investments | $388.95M | $320.56M | $275.85M | $333.29M | +21.3% |
| Accounts receivable | $26.08M | $18.51M | $14.87M | $6.22M | +40.9% |
| Inventory | $25.75M | $18.74M | $8.62M | $2.92M | +37.4% |
| Total current assets | $466.92M | $374.20M | $308.27M | $354.24M | +24.8% |
| Property, plant & equipment | $4.15M | $4.11M | $2.12M | $3.38M | +1.1% |
| Goodwill & intangibles | $5.32M | $6.17M | $7.03M | $7.88M | -13.8% |
| Total assets | $480.20M | $392.27M | $332.75M | $382.48M | +22.4% |
| Total current liabilities | $105.94M | $115.52M | $55.20M | $39.81M | -8.3% |
| Total debt | $3.99M | $3.94M | $1.26M | $1.94M | +1.4% |
| Total liabilities | $210.17M | $227.72M | $162.99M | $118.22M | -7.7% |
| Retained earnings | -$1.35B | -$1.16B | -$894.74M | -$710.06M | -17.0% |
| Shareholder equity | $270.03M | $164.55M | $169.76M | $264.26M | +64.1% |
| Working capital | $360.97M | $258.68M | $253.06M | $314.43M | +39.5% |
| Net tangible assets | $264.71M | $158.38M | $162.73M | $256.38M | +67.1% |
| Shares issued | 67.21M | 62.39M | 59.43M | 56.61M | +7.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$196.54M | -$260.60M | -$184.68M | -$181.12M | — | +24.6% |
| Depreciation & amortisation | $1.34M | $1.56M | $1.76M | $1.67M | — | -14.4% |
| Stock-based compensation | $66.82M | $39.68M | $32.55M | $19.83M | — | +68.4% |
| Change in working capital | -$968.00K | $10.57M | $4.81M | -$17.41M | — | -109.2% |
| Operating cash flow | -$115.67M | -$113.88M | -$136.16M | -$173.43M | — | -1.6% |
| Capital expenditure | -$953.00K | — | -$47.00K | -$4.28M | -$5.43M | — |
| Investing cash flow | -$137.15M | -$48.17M | -$5.67M | $28.03M | — | -184.7% |
| Financing cash flow | $217.96M | $191.24M | $74.37M | $213.83M | — | +14.0% |
| Free cash flow | -$116.63M | -$113.88M | -$136.20M | -$177.71M | — | -2.4% |
| End cash position | $54.82M | $89.60M | $60.41M | $128.00M | — | -38.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $71.25M | $60.11M | $57.25M | $51.30M | $48.50M | +18.5% |
| Operating revenue | $71.25M | $60.11M | $57.25M | $51.30M | $48.50M | +18.5% |
| Cost of revenue | $8.93M | $7.16M | $4.80M | $5.50M | $5.54M | +24.8% |
| Gross profit | $62.32M | $52.95M | $52.45M | $45.80M | $42.96M | +17.7% |
| Research & development | $43.43M | $41.73M | $42.03M | $46.03M | $42.31M | +4.1% |
| Selling, general & admin | $67.45M | $63.59M | $57.48M | $52.42M | $45.95M | +6.1% |
| Total operating expense | $110.88M | $105.32M | $99.51M | $98.45M | $88.25M | +5.3% |
| Operating income | -$48.55M | -$52.36M | -$47.06M | -$52.65M | -$45.30M | +7.3% |
| Net interest income | -$1.32M | -$1.03M | -$530.00K | -$414.00K | -$2.58M | -28.3% |
| Pre-tax income | -$48.85M | -$55.09M | -$47.54M | -$52.79M | -$46.30M | +11.3% |
| Tax provision | $444.00K | $545.00K | -$31.00K | $111.00K | $337.00K | -18.5% |
| Net income | -$49.30M | -$55.64M | -$47.51M | -$52.90M | -$46.63M | +11.4% |
| Net income to common | -$50.36M | -$56.74M | -$48.84M | -$54.28M | -$47.98M | +11.2% |
| Basic EPS | -0.73 | -0.83 | -0.73 | -0.82 | -0.75 | +12.0% |
| Diluted EPS | -0.73 | -0.83 | -0.73 | -0.82 | -0.75 | +12.0% |
| EBIT | -$44.31M | -$50.51M | -$42.92M | -$48.05M | -$40.48M | +12.3% |
| EBITDA | -$44.06M | -$50.26M | -$42.65M | -$47.75M | -$40.10M | +12.3% |
| Basic shares | 68.59M | 67.97M | 66.88M | 66.26M | 63.68M | +0.9% |
| Diluted shares | 68.59M | 67.97M | 66.88M | 66.26M | 63.68M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $65.61M | $62.14M | $54.30M | $52.08M | $135.59M | +5.6% |
| Cash & short-term investments | $330.90M | $340.63M | $388.95M | $416.05M | $291.03M | -2.9% |
| Accounts receivable | $40.41M | $34.19M | $26.08M | $33.03M | $26.12M | +18.2% |
| Inventory | $30.52M | $28.65M | $25.75M | $22.11M | $18.87M | +6.5% |
| Total current assets | $426.56M | $430.09M | $466.92M | $494.80M | $360.68M | -0.8% |
| Property, plant & equipment | $2.92M | $4.00M | $4.15M | $3.40M | $3.56M | -27.0% |
| Goodwill & intangibles | $4.89M | $5.11M | $5.32M | $5.53M | $5.75M | -4.2% |
| Total assets | $437.27M | $442.32M | $480.20M | $506.87M | $372.73M | -1.1% |
| Total current liabilities | $123.59M | $103.20M | $105.94M | $104.27M | $129.46M | +19.8% |
| Total debt | $3.68M | $3.84M | $3.99M | $4.14M | $4.19M | -4.1% |
| Total liabilities | $219.97M | $204.70M | $210.17M | $211.19M | $239.15M | +7.5% |
| Retained earnings | -$1.46B | -$1.41B | -$1.35B | -$1.30B | -$1.25B | -3.5% |
| Shareholder equity | $217.30M | $237.62M | $270.03M | $295.68M | $133.58M | -8.5% |
| Working capital | $302.98M | $326.89M | $360.97M | $390.54M | $231.22M | -7.3% |
| Net tangible assets | $212.41M | $232.51M | $264.71M | $290.15M | $127.84M | -8.6% |
| Shares issued | 68.82M | 68.45M | 67.21M | 66.68M | 63.91M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$49.30M | -$55.64M | -$47.51M | -$52.90M | -$46.63M | +11.4% |
| Depreciation & amortisation | $251.00K | $252.00K | $272.00K | $304.00K | $379.00K | -0.4% |
| Stock-based compensation | $26.06M | $23.10M | $19.27M | $18.81M | $15.88M | +12.8% |
| Change in working capital | $10.65M | -$17.01M | -$691.00K | $3.11M | $4.53M | +162.6% |
| Operating cash flow | -$9.15M | -$44.19M | -$25.39M | -$26.62M | -$23.31M | +79.3% |
| Investing cash flow | $14.01M | $57.05M | $30.35M | -$246.35M | $54.03M | -75.4% |
| Financing cash flow | -$1.17M | -$5.40M | -$2.95M | $189.30M | -$889.00K | +78.4% |
| Free cash flow | -$9.15M | -$44.19M | -$26.34M | -$26.62M | -$23.31M | +79.3% |
| End cash position | $66.22M | $62.74M | $54.82M | $52.75M | $136.11M | +5.5% |
Options analytics
Put / call volume
0.39
Call-heavy session
Put / call open interest
0.20
Positioning, not flow
Max pain
90.00
-0.8% from spot
ATM implied vol
235.4%
Nearest strike to spot
Skew (10% OTM)
+19.6%
Puts bid over calls
Call volume
33
Contracts, this expiry
Put volume
13
Contracts, this expiry
Heaviest call OI
120.00
102 contracts
Heaviest put OI
65.00
16 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.83 | -0.73 | +12.4% |
| Mar 2026 | -0.86 | -0.83 | +3.6% |
| Dec 2025 | -0.78 | -0.73 | +6.4% |
| Sep 2025 | -0.73 | -0.82 | -11.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.76 | 12 | $83.68M | +63.1% |
| Next quarter | -0.75 | 12 | $97.84M | +70.9% |
| Current year | -3.10 | 12 | $313.30M | +65.1% |
| Next year | -0.61 | 12 | $558.34M | +78.2% |
Analyst targets & ownership
Mean target$138.59
High target$160.00
Low target$105.00
Implied upside52.68%
Analyst count17
ConsensusNONE
Strong buy / Buy5 / 11
Hold2
Sell / Strong sell0 / 0
Held by insiders0.70%
Held by institutions114.84%
Institutions holding428
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
95.42
-4.87% from price
SMA 20
97.71
-7.10% from price
SMA 50
104.91
-13.48% from price
SMA 100
101.83
-10.86% from price
SMA 200
98.68
-8.02% from price
EMA 12
95.40
-4.85% from price
EMA 26
98.91
-8.23% from price
EMA 50
101.41
-10.50% from price
RSI (14)
26.1
Oversold
MACD (12,26,9)
-3.51
Hist -0.46
ATR (14)
3.53
3.88% of price
Realised vol 30D
27.8%
Annualised
Bollinger upper
104.63
20, 2σ
Bollinger lower
90.78
20, 2σ
50 / 200 cross
Golden
104.91 vs 98.68
Trend bias
Below 200
-8.02%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.00
Less volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
27.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-35.5%
Peak to trough
Max drawdown 5Y
-77.6%
Peak to trough
ATR 14
3.53
3.88% of price
Beta (reported)
2.01
5Y monthly, from filing
Short interest
Shares short
10.29M
Prior 10.15M
Change vs prior
+1.3%
Shorts adding
% of float
15.06%
Elevated
% of shares out
14.94%
Against total outstanding
Days to cover
20.6
Crowded exit
Float
56.04M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 28, 26 | Deutsche Bank | INITIATED | — | Hold |
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 5, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 5, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jul 27, 26 | JP Morgan | INITIATED | — | Overweight |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 16, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jun 15, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| May 7, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 6, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-15
Proxy Statements
DEFA14A · 2026-05-29
Periodic Financial Reports
10-Q · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-03
Corporate Changes & Voting Matters
8-K · 2026-03-26
Headlines
Rhythm Pharmaceuticals Gains Health Canada Approval for Imcivree
MT Newswires · 15d ago
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
GlobeNewswire · 15d ago
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Zacks · 19d ago
Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform
MT Newswires · 20d ago
Rhythm Pharmaceuticals Insider Sold Shares Worth $5,133,442, According to a Recent SEC Filing
MT Newswires · 22d ago
Billionaire Stanley Druckenmiller’s 2 New Healthcare Stock Picks
Insider Monkey · 26d ago
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
GlobeNewswire · 27d ago
An AI drug specialist zeroes in on rare forms of obesity
BioPharma Dive · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.